Persica Pharmaceuticals

Persica Pharmaceuticals is pioneering a novel, non-opioid treatment for chronic low back pain (cLBP) driven by Modic changes, which are believed to be caused by a bacterial infection in vertebral discs. Its lead asset, PP353, is a patented, targeted intradiscal antibiotic injection designed to deliver high local drug concentration with a single administration, minimizing systemic side effects. The company is led by an experienced team with strong track records in drug development and biotech financing, and it has published promising efficacy data for PP353 in a peer-reviewed journal. Persica is targeting a significant unmet need in a large, identifiable patient population with limited effective treatment options.

Patented platform for targeted local delivery of therapeutics (specifically antibiotics via intradiscal injection) to achieve high drug concentration at the site of disease while minimizing systemic exposure.

PP353 is a first-in-class candidate targeting the underlying pathology of Modic change-associated cLBP. It faces indirect competition from generic pain management (NSAIDs, opioids, steroids) and spinal procedures, but no other pharmaceutical directly targets the proposed infectious mechanism.